Background: Novel regimens have revolutionized multidrug-resistant tuberculosis (MDR-TB) treatment; however, medication adherence remains challenging and poorly characterized. We hypothesized that bedaquiline adherence, measured using electronic dose monitoring, would predict MDR-TB treatment outcomes.
Setting: This is a prospective cohort study conducted in KwaZulu-Natal, South Africa.
Methods: Adults with MDR-TB and HIV initiating bedaquiline and on antiretroviral therapy (ART) were eligible. Separate electronic dose monitoring devices measured bedaquiline and ART adherence through 6 months, calculated as observed versus expected doses. Whole-genome sequencing was performed to identify bedaquiline resistance-associated variants.
Results: From November 2016 through February 2018, 199 participants with MDR-TB and HIV were enrolled and followed up through treatment completion (median 17.2 months interquartile range 12.2-19.6). The median bedaquiline adherence was higher than ART adherence (97 vs. 89%, P < 0.001) but correlated (r2 = 0.68, P < 0.001). High bedaquiline adherence (≥90%) compared with lower adherence was associated with improved end of treatment successful outcome (83.4% vs. 46.3%, P < 0.001), decreased mortality (11.0% vs. 29.6% P = 0.004), and improved retention in care through end of treatment (94.5% vs. 79.6% P = 0.002). Modeling identified a highly significant but linear association between bedaquiline adherence and outcome. On multivariable analysis, bedaquiline adherence was independently associated with mortality and outcome. Bedaquiline resistance-associated variants were seen in 12% (7/57) of sequenced isolates (7% baseline, 5% emergent) with only 28.6% experiencing successful treatment outcome.
Conclusions: Bedaquiline adherence through 6 months independently predicted end of MDR-TB treatment outcome, but a specific bedaquiline adherence threshold was not identified. Interventions to optimize bedaquiline adherence are urgently needed to improve MDR-TB HIV treatment outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11077859 | PMC |
| http://dx.doi.org/10.1097/QAI.0000000000002940 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Model-Informed Once-Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis.
Clin Pharmacol Ther
December 2024
Department of Pharmacy, Uppsala University, Uppsala, Sweden.
The complexity of the currently registered dosing schedules for bedaquiline and delamanid is a barrier to uptake in drug-resistant tuberculosis treatment across all ages. A simpler once-daily dosing schedule is critical to ensure patient-friendly regimens with good adherence. We assessed expected drug exposures with proposed once-daily doses for adults and compared novel model-informed once-daily dosing strategies for children with current World Health Organization (WHO) recommended dosing.
View Article and Find Full Text PDFEvaluation of health-related quality of life and adherence among pre-extensively drug-resistant tuberculosis patients receiving either Bedaquiline or Delamanid regimen at a teaching hospital in Eastern India.
J Family Med Prim Care
October 2024
Department of Pharmacology, Kalinga Institute of Medical Sciences, KIIT Deemed to be University, Bhubaneswar, Odisha, India.
Background: The foremost concern and challenge in managing drug-resistant tuberculosis is ensuring a high health-related quality of life (HRQoL). The effectiveness of pre-extensively drug-resistant (Pre-XDR) tuberculosis management hinges on patients adhering to therapy, a crucial factor in averting the development of drug-resistant strains, ultimately enhancing HRQoL.
Methodology: This analytical longitudinal study spanned two years at a teaching hospital and involved collaboration between the Departments of Pharmacology and Pulmonary Medicine.
Introducing BPaL: Experiences from countries supported under the LIFT-TB project.
PLoS One
November 2024
KNCV Tuberculosis Foundation, The Hague, The Netherlands.
Article Synopsis
- * The LIFT-TB project, involving 7 countries, focused on implementing BPaL under operational research conditions, aiming to assess its feasibility, effectiveness, and safety for selected DR-TB patients.
- * Interim results from November 2020 to March 2023 indicate a high treatment success rate of 90.9% among 574 enrolled patients, with manageable adverse effects and no unexpected complications, demonstrating the
Safety of single-dose bedaquiline combined with rifampicin for leprosy post-exposure prophylaxis: A Phase 2 randomized non-inferiority trial in the Comoros Islands.
PLoS Med
October 2024
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Article Synopsis
- The World Health Organization recommends the use of single-dose rifampicin (SDR) for leprosy post-exposure prophylaxis (PEP), potentially reducing leprosy risk by about 50% in contacts of patients.
- A Phase 2 trial tested a new PEP regimen that combines bedaquiline with rifampicin (BE-PEP) against the standard therapy (SDR-PEP), focusing on safety and QT interval changes in patients.
- The trial, involving 313 participants, demonstrated that BE-PEP did not significantly differ from SDR-PEP regarding QT interval changes after treatment, indicating comparable safety profiles between the two regimens.
Novel Treatment for Pre-XDR Tuberculosis Linked to a Lethal Case of Acute Myocarditis.
Diagnostics (Basel)
September 2024
Adult ICU, General Hospital of Thessaloniki "Hippokration", National Healthcare System, 54642 Thessaloniki, Greece.
Article Synopsis
- The report discusses a case of a 48-year-old patient with pre-extensively drug-resistant tuberculosis (XDR tb) who died from myocarditis following a complex treatment regimen.
- The patient's history of poor adherence to medication resulted in acquired resistance to both first- and second-line drugs, complicating her condition.
- This case highlights a potentially lethal side effect of drug treatment for resistant tb, urging clinicians to be vigilant about the risk of drug-induced myocarditis in similar patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!